Sources of serum [14C]-octanoate in cirrhosis of the liver and hepatic encephalopathy.
Serum octanoate levels of patients with liver cirrhosis and hepatic encephalopathy have been shown to be three to 15 times higher than those of controls. Assays for octanoate have been modified to permit isolation of pure octanoate after GLC. Patients with these conditions were given intravenously differently labeled [14C]-palmitates; serum [14C]-octanoate was isolated in each case and shown by mass spectrometry to be authentic octanoate. [1-14C]-oleate and [1-14C]-stereate were also shown to serve as precursors of serum [14C]-octanoate. When differently labeled palmitates (1-[14C]; omega [14C]; and [14C]-uniformly labeled) were used, different yields of serum [14C]-octanoate were recovered. Octanoate samples were chemically degraded to yield individual carbons or groups of carbons. In this manner it was possible to determine the percentage distribution of the [14C] label within the octanoate carbon chain. The data obtained from these studies suggest that 60% to 80% of the serum octanoate was obtained from the incomplete beta-oxidation of long-chain fatty acids and that 20% to 40% of the octanoate may have been formed de novo.
D002210:Caprylates / Q000097:blood* / Q000378:metabolism; D005227:Fatty Acids / Q000378:metabolism; D006501:Hepatic Encephalopathy / Q000097:blood / Q000378:metabolism*; D006801:Humans; D066298:In Vitro Techniques; D008103:Liver Cirrhosis / Q000097:blood / Q000378:metabolism*; D010084:Oxidation-Reduction; D010168:Palmitates / Q000378:metabolism; D011168:Portal System / Q000502:physiology
D002210:Caprylates; D005227:Fatty Acids; D010168:Palmitates